:format(webp)/cloudfront-us-east-1.images.arcpublishing.com/tgam/REVUNACPJZJBPEGMZIJCZ46E2A.jpg)
The Bausch Health headquarters stands in Laval, Que., on Feb. 20, 2019.Ryan Remiorz/The Canadian Press
Canadian drugmaker Bausch Health Companies Inc on Thursday named insider Sam Eldessouky as its new finance chief, at a time when the Canadian drugmaker looks to speed up the spinoff of eye care unit Bausch + Lomb.
Current CFO Paul Herendeen will take on the role of advisor to the chairman and chief executive officer, the company said.
Eldessouky’s appointment comes amid calls from activist investor Glenview Capital Management for Bausch to spin-off Bausch + Lomb by year-end. The company in August said it would offload the unit into a separate publicly listed firm.
Bausch last month agreed to add directors from Icahn Group to its board, weeks after activist investor Carl Icahn disclosed a nearly 8 per cent stake.
Eldessouky joined Bausch Health, previously known as Valeant Pharmaceuticals, in 2016 as senior vice president and corporate controller.
Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.